MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

Xilio Development Inc

Healthcare US XLO

1.3201USD
0.33(33.34%)

Last update at 2024-10-30T18:56:00Z

Day Range

1.031.40
LowHigh

52 Week Range

0.493.25
LowHigh

Fundamentals

  • Previous Close 0.99
  • Market Cap33.86M
  • Volume3051155
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-77.23300M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -56.77400M
  • Diluted EPS TTM-2.25

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -88.22200M -75.80000M -55.21900M -17.31100M
Minority interest - - - -
Net income -87.29500M -74.30100M -55.21900M -17.31100M
Selling general administrative 29.95M 23.86M 10.65M 4.77M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 1.85M 1.50M 1.06M 0.24M
Ebit -90.99600M -76.54300M -54.56300M -19.02700M
Ebitda -89.14900M -75.04400M -53.49800M -18.78700M
Depreciation and amortization 1.85M 1.50M 1.06M 0.24M
Non operating income net other 0.93M -0.75600M - -
Operating income -89.14900M -75.04400M -54.56300M -19.02700M
Other operating expenses 89.15M 75.04M 54.56M 19.03M
Interest expense -0.92700M 0.76M 0.00000M 0.00000M
Tax provision - - - -
Interest income - - - -
Net interest income - - - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.92700M -1.49900M 0.66M -1.71600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 89.15M 75.04M 54.56M 19.03M
Cost of revenue - - - -
Total other income expense net 0.93M -0.75600M -0.65600M 1.72M
Discontinued operations - - - -
Net income from continuing ops -88.22200M -75.80000M -55.21900M -17.31100M
Net income applicable to common shares -88.22200M -75.80000M -55.21900M -17.31100M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 60.93M 139.16M 218.06M 36.32M 62.72M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.42M 4.11M 4.46M 0.04M 1.01M
Total liab 24.10M 33.52M 32.63M 119.60M 92.25M
Total stockholder equity 36.83M 105.65M 185.43M -83.28700M -29.52300M
Deferred long term liab - - - - -
Other current liab 10.50M 10.41M 0.08M 0.08M 2.69M
Common stock 0.00300M 0.00300M 0.00300M 0.00100M -
Capital stock - 0.00300M 0.00300M 0.00000M 0.00000M
Retained earnings -325.51200M -249.10800M -160.88600M -85.08600M -29.86700M
Other liab - - 32.63M 0.54M 0.37M
Good will - - - - -
Other assets - 1.61M 231.66M 2.05M 1.75M
Cash 44.70M 120.39M 198.05M 19.24M 48.84M
Cash and equivalents - - - - -
Total current liabilities 15.96M 21.12M 12.78M 22.16M 5.21M
Current deferred revenue - - 8.75M 13.73M -
Net debt -32.15200M -100.44600M -177.51700M 1.98M -30.21400M
Short term debt 4.41M 7.58M 0.80M 2.90M -
Short long term debt - 6.67M - 2.33M -
Short long term debt total 12.55M 19.94M 20.54M 21.22M 18.63M
Other stockholder equity 362.34M 354.75M 346.31M 1.80M 0.34M
Property plant equipment - 7.25M 13.60M 13.68M 9.87M
Total current assets 48.13M 124.50M 202.52M 20.59M 51.10M
Long term investments - - - - -
Net tangible assets - 105.65M 185.43M -83.28700M -29.52300M
Short term investments - - - - -
Net receivables - 0.27M 0.39M - -
Long term debt - 3.17M 9.63M 7.41M 9.61M
Inventory - - - - -
Accounts payable 1.05M 3.12M 3.14M 5.44M 2.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -218.06000M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00300M 0.00300M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -249.10800M -160.88600M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.01M 1.83M 1.95M 2.05M 1.75M
Deferred long term asset charges - - - - -
Non current assets total 12.80M 14.67M 15.54M 15.73M 11.62M
Capital lease obligations - 10.11M 10.91M 11.47M 9.02M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -1.86700M -1.10000M -2.18800M -0.71500M
Change to liabilities 2.07M -8.43500M 2.93M 0.97M
Total cashflows from investing activities -1.86700M -1.10000M -2.18800M -0.71500M
Net borrowings -0.08500M -0.02500M -0.09900M 9.95M
Total cash from financing activities -0.06900M 260.67M 10.03M 60.02M
Change to operating activities 1.52M -8.98500M 13.68M -0.17300M
Net income -88.22200M -75.80000M -55.21900M -17.31100M
Change in cash -77.65900M 178.82M -28.25000M 41.46M
Begin period cash flow 199.61M 20.79M 49.04M 7.58M
End period cash flow 121.95M 199.61M 20.79M 49.04M
Total cash from operating activities -75.72300M -80.75100M -36.09100M -17.84300M
Issuance of capital stock 0.00000M 261.25M 9.97M 50.07M
Depreciation 1.85M 1.50M 1.06M 0.24M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 0.02M 261.53M - -
Other cashflows from financing activities 0.02M 145.39M 10.13M -0.71500M
Change to netincome 8.65M 5.15M 1.46M -1.56900M
Capital expenditures 1.87M 1.10M 2.19M 0.71M
Change receivables - - - -
Cash flows other operating -0.06600M -3.16500M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -77.65900M 178.82M - -
Change in working capital 2.00M -11.80300M 16.60M 0.80M
Stock based compensation 8.42M 4.96M 1.30M 0.11M
Other non cash items 0.22M 0.17M 0.04M 0.06M
Free cash flow -77.59000M -81.85100M -38.27900M -18.55800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
XLO
Xilio Development Inc
0.33 33.34% 1.32 - - - 1.10 -0.1098
NVO
Novo Nordisk A/S
1.17 1.04% 113.15 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
1.95 1.76% 112.70 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
3.92 0.83% 474.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-1.92 0.21% 925.41 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Development Inc

828 Winter Street, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Dr. Rene Russo BCPS, Pharm.D, Pharm.D. CEO & Director 1975
Dr. Martin H. Huber M.D. Pres and Head of R&D 1961
Dr. Uli Bialucha Ph.D. Chief Scientific Officer NA
Mr. Christopher Frankenfield Chief Legal & Admin. Officer NA
Julissa Viana VP of Corp. Communications NA
Mr. Bill Avery Ph.D. Sr. VP of Nonclinical Devel. NA
Ms. Stacey J. Davis Chief Bus. Officer NA
Dr. Rene Russo BCPS, Pharm.D. President, CEO & Director 1975
Mr. Kevin M. Brennan Senior VP of Finance & Accounting 1970
Mr. Christopher Frankenfield Chief Operating Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.